This is a study of pembrolizumab (KEYTRUDA) in combination of REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic cancer.
1. To determine the safety and Dose-limiting toxicities (DLTs) of Reolysin and chemotherapy (gemcitabine or irinotecan or 5FU) in combination with pembrolizumab in patients with advanced pancreatic adenocarcinoma who have progressed after ( or did not tolerate) first line treatment.
2.To determine the overall response rate (ORR), and progression-free survival (PFS) by immune-related response criteria , as well as overall survival (OS).
3. To determine the effects of Reolysin and pembrolizumab when administered in combination as determined by analysis of pre- and post-treatment biopsies and blood-based immune markers.